BACKGROUND: Concomitant hyperthermia has been shown to improve response rate after cisplatin in recurrent cervical cancer in previously irradiated patients. It is unclear whether similar response rates can be obtained in patients with a recurrence after previous platinum-containing chemoradiation. OBJECTIVE: This study aimed to evaluate the outcome of cisplatin-based chemotherapy with concurrent hyperthermia in patients with recurrent cervical cancer after radiotherapy and cisplatin. METHODS: Patients with recurrent cervical cancer after cisplatin-based chemoradiation or neoadjuvant chemotherapy followed by surgery and radiotherapy who were treated with concurrent platinum-based chemotherapy and hyperthermia were eligible for this retrospective analysis. All patients received six or eight weekly platinum-based chemotherapy cycles in combination with six or eight weekly hyperthermia sessions. The time-to-event variables were estimated using Kaplan-Meier analysis. P-values less than 0.05 were considered significant. RESULTS: All 38 evaluable patients were selected from the hyperthermia database in the Academic Medical Centre (Amsterdam) and the Erasmus Medical Centre (Rotterdam). Mean age at relapse was 45.7 years (range 27-74). Median time to recurrence after first-line treatment was 15 months. A total of 27 patients had a local and/or regional recurrence; 11 had disease beyond the pelvis. All planned courses of cisplatin chemotherapy and hyperthermia were administered in 17/38 patients. Median follow-up was 6.5 months. One patient died during treatment; response rate was 4/37 (14%), with one complete response. Overall survival was 23% at 12 months and 4% at 24 months. The incidence of grade 3-4 haematological complications did not exceed 10%. CONCLUSION: In this retrospective study, concurrent cisplatin and hyperthermia after first-line cisplatin-containing chemoradiation showed poor response and survival. We do not recommend this treatment for recurrence of locally advanced cervical cancer.
BACKGROUND: Concomitant hyperthermia has been shown to improve response rate after cisplatin in recurrent cervical cancer in previously irradiated patients. It is unclear whether similar response rates can be obtained in patients with a recurrence after previous platinum-containing chemoradiation. OBJECTIVE: This study aimed to evaluate the outcome of cisplatin-based chemotherapy with concurrent hyperthermia in patients with recurrent cervical cancer after radiotherapy and cisplatin. METHODS:Patients with recurrent cervical cancer after cisplatin-based chemoradiation or neoadjuvant chemotherapy followed by surgery and radiotherapy who were treated with concurrent platinum-based chemotherapy and hyperthermia were eligible for this retrospective analysis. All patients received six or eight weekly platinum-based chemotherapy cycles in combination with six or eight weekly hyperthermia sessions. The time-to-event variables were estimated using Kaplan-Meier analysis. P-values less than 0.05 were considered significant. RESULTS: All 38 evaluable patients were selected from the hyperthermia database in the Academic Medical Centre (Amsterdam) and the Erasmus Medical Centre (Rotterdam). Mean age at relapse was 45.7 years (range 27-74). Median time to recurrence after first-line treatment was 15 months. A total of 27 patients had a local and/or regional recurrence; 11 had disease beyond the pelvis. All planned courses of cisplatin chemotherapy and hyperthermia were administered in 17/38 patients. Median follow-up was 6.5 months. One patient died during treatment; response rate was 4/37 (14%), with one complete response. Overall survival was 23% at 12 months and 4% at 24 months. The incidence of grade 3-4 haematological complications did not exceed 10%. CONCLUSION: In this retrospective study, concurrent cisplatin and hyperthermia after first-line cisplatin-containing chemoradiation showed poor response and survival. We do not recommend this treatment for recurrence of locally advanced cervical cancer.
Authors: Lianne E M Vriend; Nathalie van den Tempel; Arlene L Oei; Mike L'Acosta; Frederique J Pieterson; Nicolaas A P Franken; Roland Kanaar; Przemek M Krawczyk Journal: Oncotarget Date: 2017-10-27
Authors: Arlene L Oei; Lianne E M Vriend; Caspar M van Leeuwen; Hans M Rodermond; Rosemarie Ten Cate; Anneke M Westermann; Lukas J A Stalpers; Johannes Crezee; Roland Kanaar; H Petra Kok; Przemek M Krawczyk; Nicolaas A P Franken Journal: Oncotarget Date: 2017-03-07
Authors: Nathalie van den Tempel; Kishan A T Naipal; Anja Raams; Dik C van Gent; Martine Franckena; Joost L Boormans; Roland Kanaar Journal: PLoS One Date: 2018-12-14 Impact factor: 3.240
Authors: Arlene L Oei; Lianne E M Vriend; Johannes Crezee; Nicolaas A P Franken; Przemek M Krawczyk Journal: Radiat Oncol Date: 2015-08-07 Impact factor: 3.481
Authors: Pauline C Guillemin; Laura Gui; Orane Lorton; Thomas Zilli; Lindsey A Crowe; Stéphane Desgranges; Xavier Montet; Sylvain Terraz; Raymond Miralbell; Rares Salomir; Sana Boudabbous Journal: J Transl Med Date: 2019-10-24 Impact factor: 5.531